This month on Synapse
Taylor Wessing and Willkie Farr & Gallagher present the first of three webinars covering various aspects of market access for biosimilars. In this webinar they cover the basics of the regulatory system in the US and Europe; the history of approvals and launches in the US and Europe; and an overview of the "patent dance" under the BPCIA and contrast to the position in Europe.
Topical issues
Nick Harrison explains what is in the Department of Health and Social Care (DHSC) has published in its initial Code of Conduct for the use of data-driven technology in the health and care sectors.
In the first of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Tim Worden and Paul England examine the Government's 'Chequers' offer to the UK on a future relationship.
In the second of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Paul England examines the relevance of the transition (implementation) period.
In the final article about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Matthew Royle and Paul England address the guidelines issued by the UK Government and EU Commission in the event of a ‘no deal’ Brexit.
Paul England provides the latest on the Truvada supplementary protection certificate case in the UK.
